29.75
-0.84 (-2.75%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Insurance - Life (US) | Menurun | Menurun |
| Insurance - Life (Global) | Menurun | Bercampur | |
| Stok | Ethos Technologies Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -1.13 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| Sektor | Financial Services |
| Industri | Insurance - Life |
| Gaya Pelaburan | Small Value |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (Goldman Sachs, 10.92%) | Beli |
| Median | 19.00 (-36.13%) | |
| Rendah | 13.00 (JP Morgan, -56.30%) | Beli |
| Purata | 19.88 (-33.18%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 11.22 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 26 Feb 2026 | 16.00 (-46.22%) | Beli | 12.28 |
| 23 Feb 2026 | 15.00 (-49.58%) | Beli | 11.00 | |
| Deutsche Bank | 24 Feb 2026 | 23.00 (-22.69%) | Beli | 11.44 |
| B of A Securities | 23 Feb 2026 | 15.00 (-49.58%) | Beli | 11.00 |
| Baird | 23 Feb 2026 | 18.00 (-39.50%) | Beli | 11.00 |
| Barclays | 23 Feb 2026 | 20.00 (-32.77%) | Beli | 11.00 |
| Citizens | 23 Feb 2026 | 21.00 (-29.41%) | Beli | 11.00 |
| Goldman Sachs | 23 Feb 2026 | 33.00 (10.92%) | Beli | 11.00 |
| JP Morgan | 23 Feb 2026 | 13.00 (-56.30%) | Beli | 11.00 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |